ARGS

-- -- --

from December 31, 2016 to January 19, 2018 Issuance of common stock under ATM Issuance of common stock as payment of debt Issuance of restricted common stock to employees Issuance of common stock under ESPP On January 18, 2018 (the “Effective Date”), Argos Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which effected, as of 5:00 p.m., Eastern Time, on the Effective Date, a one-for-twenty reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, $0.001 par value per share (the “Common Stock”).

from December 31, 2015 to December 31, 2016 Issuance of common stock and warrants Issuance of restricted common stock to employees Issuance of fully vested common stock to directors Issuance of common stock under ESPP Exercise of common stock options Exercise of warrants

At the closing of the initial tranche in March 2016, we sold and the investors purchased, for a total purchase price of approximately $19.9 million, a total of 3,652,430 shares of common stock and warrants to purchase a total of 2,739,323 shares of common stock (0.75 shares of common stock for each share of common stock purchased), based on a purchase price per share of common stock and accompanying warrant equal to $5.44375.

from December 31, 2014 to December 31, 2015 Issuance of common stock Exercise of common stock options Issuance of common stock under employee stock purchase plan

from December 31, 2013 to December 31, 2014 Issuance of common stock Exercise of common stock options Conversion of warrants into common stock Conversion of preferred stock into common stock A one-for-six reverse stock split of our common stock that became effective on January 17, 2014

from December 31, 2013 to September 30, 2014 Shares converted to common stock A one-for-six reverse stock split of our common stock that became effective on January 17, 2014

from December 31, 2013 to June 30, 2014 Shares converted to common stock A one-for-six reverse stock split of our common stock that became effective on January 17, 2014

from December 31,2013 to March 31, 2014 Shares converted to common stock Effect to a one-for-six reverse stock split of common stock that became effective on January 17, 2014.

On February 12, 2014, the Company completed its initial public offering in which it issued and sold 6,228,725 shares of common stock, including 603,725 shares of common stock sold pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock, at a price to the public of $8.00 per share. The total net proceeds raised were $43.7 million after deducting underwriting discounts and commissions of $3.5 million and other offering expenses of approximately $2.6 million. Upon the closing of the initial public offering, all of the then-outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into 13,188,251 shares of common stock.

A one-for-six reverse stock split of our common stock that became effective on January 17, 2014 The automatic conversion of all outstanding shares of our preferred stock into 13,188,251 shares of our common stock upon the closing of this offering

from December 31, 2012 to January 21, 2014 Exercise of common stock options Issuance of restricted stock Distribution of shares to affiliates Surrender of shares All information in this prospectus gives effect to a one-for-six reverse stock split of common stock that became effective on January 17, 2014.

from December 31, 2012 to September 30, 2013 Issuance of restricted stock Surrender of shares